Lightlake Therapeutics Inc.
445 Park Avenue, 9th Floor
New York
New York
10022
United Kingdom
Tel: 212-829-5546
Fax: 917-322-2105
46 articles about Lightlake Therapeutics Inc.
-
Lightlake Announces Adapt Pharma To Offer All U.S. High Schools A Free Narcan (Naloxone Hydrochloride) Nasal Spray And Fund School-Based Opioid Overdose Education
1/27/2016
-
Lightlake Announces Adapt Pharma Facilitates NARCAN (Naloxone Hydrochloride) Nasal Spray Access To 62,000 State And Local Public Entities
1/19/2016
-
Lightlake Announces Collaboration With NIDA And The Perelman School Of Medicine At The University of Pennsylvania
12/23/2015
-
Lightlake Receives Milestone Payment For U.S. FDA Approval Of NARCAN (Naloxone Hydrochloride) Nasal Spray
12/15/2015
-
Lightlake Release: NARCAN (Naloxone Hydrochloride) Nasal Spray Approved By FDA
11/19/2015
-
Lightlake Therapeutics Inc. Receives Second Funding Commitment From A Prominent International Research And Development Foundation
10/1/2015
-
Lightlake Therapeutics Inc. Announces FDA Accepts For Review Adapt Pharma's NARCAN (Naloxone Hydrochloride) Nasal Spray NDA And Grants Priority Review Status
9/25/2015
-
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan (naloxone) Nasal Spray
7/30/2015
-
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
6/3/2015
-
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
4/22/2015
-
Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
3/9/2015
-
Lightlake Therapeutics Inc., Licensor Of A Treatment To Reverse Opioid Overdoses, To Webcast Live, At VirtualInvestorConferences.com March 5th
2/27/2015
-
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose
2/17/2015
-
Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
2/9/2015
-
Lightlake Therapeutics Inc., Adapt Pharma Forge Deal Worth $55 Million
12/16/2014
-
Lightlake Therapeutics Inc. Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
12/4/2014
-
Lightlake Therapeutics Inc. Announces Closing Of Investments In Two Products
10/2/2014
-
Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
7/30/2014
-
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
7/23/2014
-
Lightlake Therapeutics Inc. Signs Agreement With Commercial Contract Manufacturer For Its Opioid Overdose Reversal Treatment
7/9/2014